A Phase 3, Randomized, Double-blind, Add-on Study Evaluating the Safety and Efficacy of Navtemadlin Plus Ruxolitinib vs Placebo Plus Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
A Phase 3, Randomized, Double-blind, Add-on Study Evaluating the Safety and Efficacy of Navtemadlin Plus Ruxolitinib vs Placebo Plus Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
This clinical trial is evaluating whether addition of navtemadlin to ruxolitinib treatment will provide more clinical benefit than ruxolitinib alone for patients with Myelofibrosis who have a suboptimal response to ruxolitinib treatment alone.
Subjects will start by receiving ruxolitinib alone in the run-in period. Those who demostrate a suboptimal response from ruxolitinib alone will then be randomized 2:1 to receive navtemadlin or navtemadlin placebo as add-on treatment to their ongoing ruxolitinib. Randomized means that subjects will be assigned to a group by chance, like a flip of a coin. The study is blinded, meaning the subjects, doctors, central endpoint assessors and sponsor will not know which add on treatment (navtemadlin or navtemadlin placebo) the subject is receiving.
Inclusion Criteria for Ruxolitinib Alone Period:
Exclusion Criteria for Ruxolitinib Alone Period:
Inclusion Criteria for Randomized Period:
Exclusion Criteria for Randomized Period:
jmei@kartosthera.com650-542-0136
Torrance, California 90502, United States
Washington D.C., District of Columbia 20007, United States
Baltimore, Maryland 21231, United States
Detroit, Michigan 48202, United States
Lake Success, New York 11042, United States
Charleston, North Carolina 29425-8900, United States
Independence, Ohio 44131, United States
Philadelphia, Pennsylvania 19104, United States
San Antonio, Texas 78229, United States
Virginia Beach, Virginia 23456, United States
Melbourne, VIC 3000, Australia
Innsbruck, 6020, Austria
Leoben, 8700, Austria
Linz, 4020, Austria
Linz, 4021, Austria
Brno, 625 00, Czechia
Nîmes, 30900, France
Tbilisi, 0141, Georgia
Tbilisi, 0144, Georgia
Tbilisi, 0159, Georgia
Lodz, 93-513, Poland
Aveiro, 3810- 501, Portugal
Lisbon, 1649-035, Portugal
Cluj-Napoca, 400015, Romania
Târgu Mureş, 540136, Romania